Hepatic encephalopathy is a serious brain disorder that develops when a damaged liver can no longer filter harmful substances from the blood. These toxins then travel to the brain, causing symptoms ranging from mild confusion to severe drowsiness and even coma. Treatment focuses on lowering toxin levels, identifying and managing triggers, and supporting overall health to improve brain function and quality of life.

Understanding treatment goals and approaches

When a person with liver disease develops hepatic encephalopathy, the main goal of treatment is to reduce the harmful substances circulating in the blood, especially a toxin called ammonia, which is produced in the gut and normally broken down by the liver. In people with advanced liver disease such as cirrhosis, the liver loses this filtering ability, allowing ammonia and other toxins to reach the brain and affect its normal functioning.^[1]

Treatment also aims to identify and reverse the factors that trigger episodes of brain dysfunction. Common triggers include infections such as pneumonia or urinary tract infections, bleeding in the digestive system, dehydration, and use of certain medications. Addressing these underlying causes is just as important as lowering toxin levels, because without treating the trigger, symptoms may persist or worsen.^[8]

The approach to managing hepatic encephalopathy varies depending on the severity of symptoms, the stage of liver disease, and individual patient characteristics. Some people experience only mild, barely noticeable symptoms called covert hepatic encephalopathy, while others have obvious signs like confusion, personality changes, or drowsiness, known as overt hepatic encephalopathy. Up to 40 percent of people with cirrhosis will develop overt hepatic encephalopathy at some point in their lives, and this marks a critical turning point in the course of their disease, with survival dropping significantly if the condition is not managed.^[8]

Medical guidelines from professional societies recommend a combination of standard medications to lower ammonia, careful monitoring, and supportive care. At the same time, researchers are exploring new therapies in clinical trials to find more effective and better-tolerated treatments. Understanding all available options, from established drugs to experimental approaches, helps patients and caregivers make informed decisions about care.^[3]

Standard medical treatment

The cornerstone of standard treatment for hepatic encephalopathy involves medications that reduce the production or absorption of ammonia in the gut. The most commonly used drug is lactulose, a synthetic sugar that has been used for this purpose since the 1960s. Lactulose works by drawing water into the intestines and creating a mild diarrhea, which helps flush out ammonia-producing bacteria and toxins before they can be absorbed. It also lowers the acidity of the stool, which traps ammonia in a form that cannot be absorbed into the bloodstream.^[15]

Lactulose is usually given as a liquid and is taken multiple times per day. The dose is adjusted so that the patient has two to three soft bowel movements daily. This ongoing effect is necessary to continuously reduce ammonia levels. While lactulose is effective, it can cause side effects such as bloating, gas, abdominal cramping, and diarrhea, which some patients find uncomfortable. However, these side effects are generally manageable and are a sign that the medication is working.^[13]

Another standard medication is rifaximin, an antibiotic that stays in the gut without being absorbed into the bloodstream. Rifaximin works by reducing the number of ammonia-producing bacteria in the intestines. It is often prescribed along with lactulose, especially for people who have repeated episodes of hepatic encephalopathy. Studies show that rifaximin reduces the risk of further episodes and hospital admissions. The usual dose is 550 milligrams taken twice a day. Because rifaximin is not absorbed, it causes fewer side effects than traditional antibiotics, though some people may experience nausea or dizziness.^[15]

Treatment duration for hepatic encephalopathy is typically long-term or even lifelong for people with cirrhosis. Once the liver is severely damaged, it cannot fully recover its filtering function, so ongoing medication is needed to prevent toxins from accumulating. Patients are encouraged to take their medications consistently, even when they feel well, because stopping treatment can lead to a relapse of symptoms.^[14]

In addition to ammonia-lowering drugs, healthcare providers focus on identifying and treating triggers that can worsen or bring on an episode of hepatic encephalopathy. Infections are the most common trigger. Doctors routinely check for infections such as spontaneous bacterial peritonitis, a serious infection of fluid in the abdomen, as well as urinary tract infections and pneumonia. Rapid treatment with antibiotics is essential, often starting even before test results confirm the infection.^[8]

Another important trigger is gastrointestinal bleeding, which can occur from swollen veins called varices in the esophagus or stomach. Blood in the digestive tract is broken down into substances that produce ammonia, worsening brain symptoms. Treatment includes stopping the bleeding and clearing blood from the intestines as quickly as possible using lactulose.^[8]

Dehydration and imbalances in body salts, or electrolytes, can also trigger hepatic encephalopathy. People with cirrhosis often take diuretics (water pills) to manage fluid buildup, but excessive use can lead to dehydration. Healthcare providers may adjust or temporarily stop diuretics and give intravenous fluids to restore balance.^[14]

Medications that affect the brain, such as sedatives, opioids, or sleeping pills, are generally avoided in people with hepatic encephalopathy, as they can worsen confusion and drowsiness. Even over-the-counter sleep aids or pain relievers can be dangerous. Patients should always check with their doctor before taking any new medication.^[14]

Nutritional support is also a key part of standard treatment. In the past, doctors thought that restricting protein in the diet would help lower ammonia levels, but research has shown this approach actually harms patients by causing malnutrition and muscle loss. Current guidelines recommend a normal or even higher protein intake, especially from plant-based sources like beans, nuts, and whole grains, which are better tolerated. Eating small, frequent meals and having a bedtime snack can help maintain energy and muscle mass.^[22]

For severe cases where standard medications are not enough, doctors may use more intensive measures. Polyethylene glycol, the same preparation used to clean the bowel before a colonoscopy, can be given to rapidly clear the intestines of ammonia-producing substances. This is especially useful in acute, severe episodes when quick action is needed.^[14]

In some cases, a procedure called liver dialysis or an artificial liver device may be used temporarily to filter toxins from the blood while the patient awaits a liver transplant or recovers from acute liver failure. However, these devices are not widely available and are used mainly in specialized centers.^[14]

For patients with very advanced liver disease and recurrent or severe hepatic encephalopathy that does not respond to medications, liver transplantation is the only definitive cure. A new, healthy liver can restore normal toxin filtering and resolve brain symptoms. However, not all patients are candidates for transplant due to age, other health conditions, or lack of available donor organs.^[13]

Treatment approaches in clinical trials

While standard treatments like lactulose and rifaximin are effective for many patients, they do not work for everyone, and some people continue to have repeated episodes of hepatic encephalopathy despite medication. This has led researchers to explore new therapies in clinical trials, testing innovative approaches that target different mechanisms involved in the disease.^[3]

One area of research focuses on manipulating the gut microbiome, the community of bacteria living in the intestines. Scientists have discovered that people with cirrhosis and hepatic encephalopathy have an imbalance in their gut bacteria, with more harmful, ammonia-producing bacteria and fewer beneficial ones. Restoring this balance might reduce ammonia production and improve brain function. Some clinical trials are testing probiotic supplements containing beneficial bacteria like Lactobacillus and Bifidobacterium to see if they can prevent or reduce episodes of hepatic encephalopathy. Early results suggest that probiotics may help, but more research is needed to identify the best strains and doses.^[15]

Another experimental approach involves medications that target ammonia production or processing in the body more directly. One such drug being studied is ornithine phenylacetate, a compound that helps the body eliminate ammonia through alternative pathways, bypassing the damaged liver. In early-phase clinical trials, this drug has shown promise in reducing blood ammonia levels in patients with acute liver failure and hepatic encephalopathy. Researchers are now testing whether it can also help people with cirrhosis-related hepatic encephalopathy.^[3]

Scientists are also investigating the role of inflammation in hepatic encephalopathy. Inflammation in the liver and throughout the body appears to worsen brain symptoms. Some trials are exploring anti-inflammatory drugs or therapies that modulate the immune system to reduce inflammation and protect the brain. These studies are in early stages, and it is not yet clear whether this approach will be effective or safe for routine use.^[9]

A particularly challenging complication of liver disease is hepatic encephalopathy that develops after a procedure called transjugular intrahepatic portosystemic shunt (TIPS). TIPS is a procedure that creates a new pathway for blood to bypass the liver, relieving pressure in the portal vein and preventing complications like bleeding varices or fluid buildup in the abdomen. However, because the shunted blood does not pass through the liver, toxins are not filtered, and up to 30 to 50 percent of patients develop hepatic encephalopathy after the procedure. Researchers are working on ways to prevent or treat post-TIPS hepatic encephalopathy, including using smaller or adjustable stents and testing medications that can be started before or immediately after the procedure.^[17]

Some clinical trials are also looking at branched-chain amino acids (BCAAs), a type of protein supplement. BCAAs are thought to compete with ammonia and other toxins for entry into the brain, potentially reducing brain symptoms. While early studies showed some benefit, more recent research has given mixed results, and BCAAs are not yet a standard recommendation. Trials are ongoing to better understand which patients might benefit most from this approach.^[22]

Phase I trials test the safety of new treatments in small groups of healthy volunteers or patients. Phase II trials evaluate whether the treatment is effective and continue to monitor safety in a larger group of patients. Phase III trials compare the new treatment with current standard therapies to determine if it offers better outcomes. Most of the experimental therapies for hepatic encephalopathy are currently in Phase I or Phase II trials, meaning they are still being evaluated for safety and effectiveness and are not yet available outside of research settings.^[3]

Clinical trials for hepatic encephalopathy are conducted in various locations, including Europe, the United States, and other countries with advanced medical research programs. Patients interested in participating in a trial should discuss options with their doctor, who can help determine eligibility and provide information about available studies. Participation in a clinical trial offers access to new treatments that are not yet widely available, but it also comes with risks and uncertainties, as the full effects and side effects of experimental therapies are still being studied.^[3]

Most common treatment methods

• Ammonia-lowering medications
  • Lactulose: a synthetic sugar that causes diarrhea to flush out ammonia and lowers stool acidity to trap ammonia in the gut, taken multiple times daily to maintain two to three soft bowel movements.^[15]
  • Rifaximin: an antibiotic that stays in the gut and reduces ammonia-producing bacteria, usually taken at 550 mg twice daily, often combined with lactulose.^[15]
  • Polyethylene glycol: a bowel preparation that rapidly clears the intestines, used in severe cases for quick ammonia removal.^[14]
• Treatment of triggers
  • Antibiotics for infections: prompt treatment of spontaneous bacterial peritonitis, urinary tract infections, and pneumonia, which are common triggers of hepatic encephalopathy.^[8]
  • Management of gastrointestinal bleeding: stopping bleeding from varices and clearing blood from the digestive tract to prevent ammonia production.^[8]
  • Correction of dehydration and electrolyte imbalances: adjusting diuretics and providing intravenous fluids to restore balance.^[14]
• Nutritional support
  • Normal or high protein intake: current guidelines recommend adequate protein, especially from plant sources, avoiding the outdated practice of protein restriction.^[22]
  • Frequent small meals and bedtime snacks: helps maintain energy and muscle mass in patients with cirrhosis.^[22]
• Advanced interventions
  • Liver dialysis or artificial liver devices: temporary support to filter toxins in severe cases, mainly used in specialized centers.^[14]
  • Liver transplantation: the only definitive cure for advanced liver disease and recurrent hepatic encephalopathy, restoring normal liver function.^[13]
• Experimental therapies in clinical trials
  • Probiotics: supplements containing beneficial bacteria to restore gut microbiome balance and reduce ammonia production, currently being tested in trials.^[15]
  • Ornithine phenylacetate: a compound that helps eliminate ammonia through alternative pathways, showing promise in early-phase trials.^[3]
  • Branched-chain amino acids: protein supplements that may compete with toxins for brain entry, with ongoing research to determine effectiveness.^[22]